Temperature check: How is the CSL (ASX:CSL) share price faring today?

How has the CSL (ASX: CSL) share price been faring lately? We take a look at its latest performance, and the broker price targets.

| More on:
A woman looks surprised as she checks an old-fashion thermometer, indicating a change in share price moevement for biotech companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has had a disappointing last couple of weeks, dragged down 9% with the broader ASX market slump in early March.

This comes despite the company posting an impressive set of numbers from its half-year results in February.

Below, we take a closer look at CSL's most recent update and how brokers view the global biotech's shares.

How did CSL perform for the first-half?

In its results, CSL reported that COVID-19 had temporarily impacted CSL Behring's performance during the first half of 2021 while boosting its Seqirus business. Despite the difference, both segments saw an increase in earnings before interest and tax (EBIT) of 24% and 112%, respectively.

This led to a surge of net profit after tax (NPAT) of $1,810 million, a jump of 44% over the prior corresponding period.

The company stated that global demand for its therapies remained strong, particularly with significant growth in seasonal influenza vaccines. The latter is due to the COVID-19 pandemic driving high rates of people getting protected from the flu.

What were the challenges?

While the results themselves were positive, CSL revealed that it continued to face some challenges.

The company advised that plasma collections remained an issue as restrictions on passenger movements affected blood donations through its collection centres.

In the United States, CSL has moved to reach out to donors through targeted marketing initiatives. This includes turning to social media influencers to encourage giving blood, as well as increased monetary incentives.

Collection volumes at the end of last year stood at 80% when compared against December 2019.

In addition, CSL had to re-prioritise some R&D projects, such as halting its efforts to develop a COVID-19 vaccine with the University of Queensland.

It found that during its Phase 1 trial, patients who were undertaking the vaccine candidate were registering as false positives on HIV tests. In light of this, the company decided not to proceed with further phase 2/3 trials.

Broker update

After reporting its first-half results, several brokers rated the company with varying price points.

The Swiss investment firm UBS cut its price target for CSL by 2.7% to $330.00. Morgan Stanley followed suit to also reduce their rating by 2.5% to $276.00, then upgraded in March to an add rating with a $301.10 price target.

According to a note out of Citi, its analysts have upgraded the biotech giant's shares to a buy rating with a $310.00 price target

The most recent broker note came from Macquarie last week, which has initiated a price of $288.00 for the biotech.

At the time of writing, the CSL share price is sitting at $261.81, up 2.33% for today. 

CSL share price review

Over the past 12 months, the CSL share price has lost around 6%, mostly from its year-to-date performance.

The company's shares moved sideways for much of the period before plummeting on its latest results release. It's worth noting that its shares today are priced the same as when they were back in November 2019.

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »